LC-200

LC-200 is a preclinical-stage liposomal formulation being developed by Lipocure Ltd. (LipocureRx) for the treatment of autoimmune and inflammatory conditions, including optic neuritis, multiple sclerosis, rheumatoid arthritis, and lupus erythematosus. The drug utilizes Lipocure's proprietary liposome-based nano-drug delivery platform, which is designed to enhance the efficacy and safety profiles of potent therapeutic agents through specialized drug-loading and controlled-release mechanisms. The pipeline is designed to follow the FDA 505(b)(2) regulatory pathway, suggesting it may be a new formulation of an existing active pharmaceutical ingredient intended to improve targeted delivery to inflamed tissues.

Other names

liposomal methylprednisoloneliposomal methylprednisolone sodium succinatenano-liposomal methylprednisolone